This site uses cookies. By using this site you agree to receiving cookies. View Policy.

129%
Raised
£518,630
Investors
407
Target
£400,000
Equity
17.18%
Pre-money valuation
£2,500,000

Gendius' mission is to make sure every person with diabetes understands their risk of complications and how to manage them. 8.5% of the world's population have diabetes and this can lead to blindness, kidney failure and amputation and increase the risk of a heart attack or stroke.

  • Over 420 million people have diabetes, growing to 629 million by 2045
  • Using artificial intelligence to help avoid complications of diabetes
  • Launched across the EU with over 3,500 downloads in EU and UK
  • Previous investment of over £1M from angel/venture capital/awards

Idea

We have been working with patients and clinicians to develop intellin, an app that takes an individual's clinical history and tells them their risk of developing complications from their diabetes and how to manage these.

Our mission is to ensure that every person with diabetes understands their risk of complications and how to manage them.

The NHS alone spends over £11 billion a year on diabetes & 80% of these costs are avoidable and linked to the complications. The personal impact of diabetes is huge with the disease leading to; blindness, kidney failure, amputation, heart attack and/or stroke.

The number of adults living with diabetes has almost quadrupled since 1980 to 422 million adults and this will reach 629 million by 2045.

We have a B2B2C offering where we will access the NHS via the NHS app store and through pilots with GP practices. The B2C offering will be via a monthly charge on the app stores.

Progress:

2017 - won part of £500K Innovate award for a clinical trial at Salford Royal NHS Foundation Trust

2017 - recieved £490K VC backing from Catapult Ventures

2017 - won £60K SBRI award for research into gestational diabetes

2018 - won £25K Momentum award to complete UX/UI research

2019 - passed ISO27001

2019 - First NHS pilot

2019 - Over 3500 downloads in UK & EU

2019 - invited to HIMSSHealth2.0 conference for a live demo of the app & 1 of 8 companies invited to pitch to investors

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the Gendius Ltd pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered?
Log in

Risk warning

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

Gendius Ltd has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.